Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Philip H. Frost"'
Autor:
Clive R. Pullinger, Patricia M. O’Connor, Josefina M. Naya‐Vigne, Steven T. Kunitake, Irina Movsesyan, Philip H. Frost, Mary J. Malloy, John P. Kane
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 7 (2021)
Background We previously showed that levels of prebeta‐1 high‐density lipoprotein (HDL), the principal acceptor of cholesterol effluxed from cells, including artery wall macrophages, are positively associated with coronary heart disease (CHD) and
Externí odkaz:
https://doaj.org/article/4bd5053424c64daf88adf626a6d457d9
Autor:
Clive R. Pullinger, Bradley E. Aouizerat, Irina Movsesyan, Vincent Durlach, Eric J. Sijbrands, Katsuyuki Nakajima, Annie Poon, Geesje M. Dallinga-Thie, Hiroaki Hattori, Lauri L. Green, Pui-Yan Kwok, Richard J. Havel, Philip H. Frost, Mary J. Malloy, John P. Kane
Publikováno v:
Journal of Lipid Research, Vol 49, Iss 8, Pp 1846-1854 (2008)
Apolipoprotein A-V (apoA-V) is an important regulator of plasma levels of triglyceride (TG) in mice. In humans, APOA5 genetic variation is associated with TG in several populations. In this study, we determined the effects of the p.185Gly>Cys (c.553G
Externí odkaz:
https://doaj.org/article/84cc271614ae4c48b6c5e75d7e56ee4b
Autor:
Elisa Campos, Leila Kotite, Patricia Blanche, Yasushi Mitsugi, Philip H. Frost, Umesh Masharani, Ronald M. Krauss, Richard J. Havel
Publikováno v:
Journal of Lipid Research, Vol 43, Iss 3, Pp 365-374 (2002)
An immunoassay procedure that quantifies remnant-like particle (RLP) cholesterol in human blood plasma has shown considerable promise as a clinically applicable risk marker for atherosclerotic disease. The lipoproteins included in this assay include
Externí odkaz:
https://doaj.org/article/386c339f41fd498f89b0164287ce8b94
Autor:
John P. Kane, Josefina Naya-Vigne, Mary J. Malloy, Clive R. Pullinger, Philip H. Frost, Patricia O’Connor, Irina Movsesyan, Steven T. Kunitake
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background We previously showed that levels of prebeta‐1 high‐density lipoprotein (HDL), the principal acceptor of cholesterol effluxed from cells, including artery wall macrophages, are positively associated with coronary heart disease (CHD) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c74ab028c2190a9afede7afedd12df33
https://doi.org/10.1161/jaha.120.018381
https://doi.org/10.1161/jaha.120.018381
Autor:
Eveline O. Stock, Mary J. Malloy, Christine T. Ferrara, Josefina Naya-Vigne, John P. Kane, Clive R. Pullinger, Philip H. Frost, Patricia O’Connor
Publikováno v:
Journal of clinical lipidology. 12(1)
Background Prebeta-1 high-density lipoprotein (HDL) is a small subspecies of HDL that functions as the HDL quantum particle and is the principal acceptor of cholesterol effluxed from macrophages through the ATP-binding cassette transporter, ABCA1. Hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1c90d324a14472438b6a8ce7818368
https://pubmed.ncbi.nlm.nih.gov/29198898
https://pubmed.ncbi.nlm.nih.gov/29198898
Autor:
Ketevan Siradze, Patricia O’Connor, Josefina Naya-Vigne, Lin T. Guey, Rita F. Redberg, Clive R. Pullinger, Christian Zellner, Brian Y. Ishida, Prakash Deedwania, John P. Kane, Omar L. Francone, Philip H. Frost, Albert B. Seymour, Mary J. Malloy, Jason M. Laramie
Publikováno v:
The American Journal of Cardiology. 108:360-366
Preβ-1 high-density lipoprotein (HDL) plays a key role in reverse cholesterol transport by promoting cholesterol efflux. Our aims were (1) to test previous associations between preβ-1 HDL and coronary heart disease (CHD) and (2) to investigate whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea650f157ce6c310c071757e2ca73ae9
https://doi.org/10.1016/j.amjcard.2011.03.054
https://doi.org/10.1016/j.amjcard.2011.03.054
Publikováno v:
Scopus-Elsevier
Uvod: Přes uspěsne zavedeni intervencni lecby akutnich koronarnich syndromů v Ceske republice průzkumy z posledni doby prokazaly, že koronarni intervence a farmakologickou lecbu je nutno kombinovat s ovlivněnim životospravy a rizikových fakto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0c248ce69f4b5e71fd27d9d7d66fa71
https://doi.org/10.33678/cor.2009.006
https://doi.org/10.33678/cor.2009.006
Autor:
Clive R. Pullinger, John P. Kane, Anthony G. Quinn, Ernst J. Schaefer, Bela F. Asztalos, Eveline O. Stock, Radhika Tripuraneni, Irina Movsesyan, Philip H. Frost, Brian Y. Ishida, Mary J. Malloy
Publikováno v:
Journal of clinical lipidology. 9(5)
Background Lysosomal acid lipase (LAL), encoded by the LIPA gene, catalyzes the intracellular hydrolysis of cholesteryl esters and triglycerides in hepatocytes and macrophages. LIPA defects cause accumulation of these lipids in lysosomes. LAL deficie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69f1ddadf6aabc3ac3816fd247b1d390
https://pubmed.ncbi.nlm.nih.gov/26350820
https://pubmed.ncbi.nlm.nih.gov/26350820
Autor:
Philip H. Frost, Pui-Yan Kwok, John P. Kane, Clive R. Pullinger, Bradley E. Aouizerat, Christian Zellner, Mary J. Malloy
Publikováno v:
Human Mutation. 25:18-21
HM74 (GPR109B) and the highly homologous gene, HM74A (GPR109A) code for Gi-G protein-coupled orphan receptors that recently have been discovered to be involved in the metabolic effects of niacin. The B vitamin niacin is an important agent used in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb3bf13a03e0b70dd2095ed92c831b38
https://doi.org/10.1002/humu.20121
https://doi.org/10.1002/humu.20121
Autor:
Mahtab Jafari, R. T. Drmanac, T. Ukrainczyk, Clive R. Pullinger, Mary J. Malloy, John P. Kane, S. Drmanac, K. Siradze, Philip H. Frost, Min Cho, David C. Heilbron, D. Gietzen
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 6:47-56
Background: The response in levels of very-low-density (VLDL) and low-density (LDL) lipoproteins varies substantially among hyperlipidemic patients during treatment with HMGCoA reductase inhibitors. Apolipoprotein E genotype and gender are known to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cadb4c5a7c853443c50cb9d5b7a7960
https://doi.org/10.1177/107424840100600106
https://doi.org/10.1177/107424840100600106